In one paragraphArticle in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Miguel Molina-BerenguerResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0001-8087-4709 Diego Herrero-MartínezPrograma de Investigación de Terapia Génica de Enfermedades Raras, División de Medicina de ADN y ARN, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.ORCID 0009-0004-7750-4861 Antoni Vallbona-GarciaResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0002-1946-3035 Ferran Vila-JuliàResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0002-3180-2749 Yolanda CámaraResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0003-2458-6942 África ValesPrograma de Investigación de Terapia Génica de Enfermedades Raras, División de Medicina de ADN y ARN, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.ORCID 0009-0000-4507-8117 Gloria González-AseguinolazaPrograma de Investigación de Terapia Génica de Enfermedades Raras, División de Medicina de ADN y ARN, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.ORCID 0000-0002-1600-4562 Javier Torres-TorronterasResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain. jtorres@barcelonabeta.org.ORCID 0000-0002-6092-9458 Ramon MartíResearch Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain. ramon.marti@vhir.org.ORCID 0000-0002-8273-9540 Funding
Dona Pilar Millan-Cromomed Fellowship 01Fundacion Adey COXPD1Fundacion Mencia DRUG4_COXPD1Fundación Mutua Madrileña (Mutua Madrileña Foundation) AP176532021Generalitat de Catalunya (Government of Catalonia) DRUG4_COXPD1Ministerio de Ciencia e Innovación (MCIN) PRTR-C17.I1
6 · The paper itselfAbstract
Hepatoencephalopathy due to mutations in the nuclear gene GFM1, known as combined oxidative phosphorylation (OXPHOS) deficiency type I (COXPD1), is an autosomal recessive mitochondrial disease caused by defects or deficiency of the mitochondrial translation elongation factor G1 (EFG1), with no currently available cure. Patients with COXPD1 develop a severe encephalopathy, sometimes combined with liver failure, with neonatal onset and rapid progression that normally causes premature death. The Gfm1
Indexed as
DependovirusGenetic TherapyMitochondrial DiseasesPeptide Elongation Factor 1AnimalsBrainDisease Models, AnimalGenetic VectorsHumansLiverMiceMice, KnockoutMitochondriaOxidative PhosphorylationPeptide Elongation Factor 1
Identifiers
PMID41998139
PMCPMC13269562
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390